Loading…
Loading…
EQUITY / NYSE · XNYS
Takeda Pharmaceutical Co Ltd ADR
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2024 – 03/31/2025 · JPY · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗18.1 USD · 0%
Observed: Oct 6, 2026, 11:57 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/06/2026 · 18.1 USD · Volume 3,098,033
21 actual observations · Latest bar: 2026-10-06 · Market data is indicative; provider terms apply.
3 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2024 – 03/31/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Revenue | 4,581,551,000,000 JPY | 4,263,762,000,000 JPY | +7.45% |
| Operating profit | 342,586,000,000 JPY | 214,075,000,000 JPY | +60.03% |
| Net income | 108,143,000,000 JPY | 144,197,000,000 JPY | -25.00% |
| Operating cash flow | 1,057,182,000,000 JPY | 716,344,000,000 JPY | +47.58% |
| Cash and cash equivalents | 385,113,000,000 JPY | 457,800,000,000 JPY | -15.88% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end04/01/2024 – 03/31/2025ConsolidatedUnits · JPY | 2024 / Year end04/01/2023 – 03/31/2024ConsolidatedUnits · JPY | 2023 / Year end04/01/2022 – 03/31/2023ConsolidatedUnits · JPY |
|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 385,113,000,000 JPY | 457,800,000,000 JPY | 533,530,000,000 JPY |
| Financing cash flowCash flow statement | -751,425,000,000 JPY | -354,416,000,000 JPY | -709,148,000,000 JPY |
| Investing cash flowCash flow statement | -367,060,000,000 JPY | -463,862,000,000 JPY | -607,102,000,000 JPY |
| Net incomeIncome statement | 108,143,000,000 JPY | 144,197,000,000 JPY | 317,038,000,000 JPY |
| Operating cash flowCash flow statement | 1,057,182,000,000 JPY | 716,344,000,000 JPY | 977,156,000,000 JPY |
| Operating profitIncome statement | 342,586,000,000 JPY | 214,075,000,000 JPY | 490,505,000,000 JPY |
| RevenueIncome statement | 4,581,551,000,000 JPY | 4,263,762,000,000 JPY | 4,027,478,000,000 JPY |
| Total assetsBalance sheet | 14,248,344,000,000 JPY | 15,108,792,000,000 JPY | — |
| Total equityBalance sheet | 6,935,979,000,000 JPY | 7,274,005,000,000 JPY | 6,354,672,000,000 JPY |
| Total liabilitiesBalance sheet | 7,312,365,000,000 JPY | 7,834,788,000,000 JPY | — |
| Report source | Open report ↗ Published: 06/25/2025 | Open report ↗ Published: 06/25/2025 | Open report ↗ Published: 06/25/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.